Form 4: Rhythm Pharma CTO Sells Shares After Option Exercise

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, exercised stock options and subsequently sold a portion of his common stock holdings.

Summary

• Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, Inc. (RYTM), engaged in multiple transactions on October 16, 2025.
• He exercised stock options to acquire 2,093 shares of common stock at an exercise price of $27.35 per share.
• He also exercised stock options to acquire an additional 12,344 shares of common stock at an exercise price of $30.66 per share.
• Following these exercises, Mr. Shulman sold a total of 14,437 shares of common stock in three separate transactions.
• The sales were executed at weighted average prices of $110.9482, $112.0554, and $112.81 per share.
• These sales were conducted pursuant to a Rule 10b5-1 instruction adopted on August 8, 2024.
• After all reported transactions, Mr. Shulman directly beneficially owns 8,509 shares of common stock.
• He also holds 14,657 stock options with an exercise price of $27.35 and an expiration date of January 31, 2033, and 10,469 stock options with an exercise price of $30.66 and an expiration date of February 10, 2031.

Sentiment

Score: 5

Explanation: The transactions involve an executive exercising options and selling shares under a pre-arranged 10b5-1 plan. While insider selling can sometimes be viewed negatively, the planned nature and the significant profit realized from exercising options at much lower prices suggest a neutral interpretation for the executive's personal financial activity, with no direct positive or negative implications for the company's operational performance or future outlook based solely on this filing.

Positives

• The executive exercised stock options at significantly lower prices ($27.35 and $30.66) compared to the sale prices (over $110 per share), indicating a substantial personal profit from long-held equity incentives.
• The sales were conducted under a Rule 10b5-1 plan, suggesting a pre-arranged liquidity event rather than a reaction to immediate negative company news.

Negatives

• A senior executive selling a significant number of shares (14,437 shares) could be perceived by some investors as a signal of reduced confidence in the company's near-term growth prospects or a desire to diversify personal holdings.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the executive's sale of shares as a personal liquidity event, especially given the 10b5-1 plan, but some might view it as a signal of the executive taking profits and potentially reducing their long-term stake.

Key Dates

Recommendation

The Chief Technical Officer's sale of shares, while significant, was executed under a pre-arranged 10b5-1 plan. This suggests a planned liquidity event for personal financial management rather than a reaction to new, undisclosed negative information about the company. The transactions involved exercising options at much lower prices and selling at significantly higher market prices, indicating a profitable personal financial move. While insider selling can sometimes signal a lack of confidence, the structured nature of these sales and the substantial profit realized suggest a 'hold' recommendation, as the underlying business fundamentals are not directly addressed by this filing and the transaction itself does not provide a clear directional signal for the company's future performance.

Keywords

Rhythm Pharmaceuticals, RYTM, Joseph Shulman, Form 4, Insider Trading, Stock Options, Share Sale, CTO, 10b5-1 Plan